Education:
Professor (Clinical) Sackler Faculty of Medicine
Academic Experience:
Professor, Sackler Faculty of Medicine
1997 - Director Division of Oncology, Tel Aviv Sourasky Medical Center
Education:
Professor (Clinical) Sackler Faculty of Medicine
Academic Experience:
Professor, Sackler Faculty of Medicine
1997 - Director Division of Oncology, Tel Aviv Sourasky Medical Center
Research Areas:
Breast Cancer – adjuvant and metastatic
Hormonal therapy in Breast Cancer
Biologics in Adjuvant and Metastatic Breast Cancer
Steering Committees of – International Studies
1) ATLAS – Academic International Study comparing 5 years of Tamoxifen to 10 years of
Tamoxifen in the Adjuvant setting.
2) HERA – Adjuvant Herceptin (sponsored by ROCHE)
3) ALTTO – Adjuvant Herceptin and Lapatinib in Breast Cancer (sponsored by GSK)
4) TURANDOT – International CECOG Study comparing Avastin + Taxol to Avastin +
Xeloda in First line Metastatic Breast Cancer (sponsored by ROCHE)
List of Publications: (2008 – 2012)
1) Adjuvant chemotherapy in oestrogen-receptor poor breast cancer: patient level meta-analysis of
randomized trials.
Early Breast Cancer Trialists Collaborative (EBCTCG).
Lancet 2008: 371: 29-40
2) Tamar Safra MD, Julia Greenberg MD, Ilan G. Ron MD, Rami Ben-Yosef MD , Moshe Inbar MD,
David Sarid MD and Neora Yaal-Hahoshen MD.
"Fulvestrant in Heavily Pretreated Metastatic Breast Cancer – Is it still effective as a very advanced line of
treatment?"
IMAJ 27/225 2008: 10:00-00
3) Benjamin W. Corn, Isaiah D. Wexler, Mohan Suntharalingam, Moshe Inbar, Walter J. Curran Jr.
"Globalization of the Radiation Therapy Oncology Group: Implementation of a Model for Service
Expansion and Public Health Improvement".
Journal of Clinical Oncology, Vol 26, No 7 (March 1), 2008: pp 1160-1166.
4) Ravit Geva MD, Irina Jiveliouk MD, Moshe Inbar MD, Isaac Meller MD, Eitan Friedman MD, PhD and
Ofer Merimsky MD, MOncol.
The Co-occurrence of Breast Cancer and Soft Tissue Sarcoma in a Single Cohort Series.
American Journal of Clinical Oncology. Volume 31, Number 6, December 2008.
5) Jiveliuk I, Corn B.W., Inbar M, Merimsky O: Ductal carcinoma in situ (DCIS) of the breast in Israeli
women treated by breast conserving surgery followed by radiation therapy. Oncology 76:30-35, 2009.
6) Corn B.W., Shabtai E., Merimsky O., Inbar M., Rosenbaum E., Meirovitz A., Wexler I.D.:
Do oncologists engage in bereavement practices? A survey of the Israeli Society of Clinical Oncology and
Radiotherapy (ISCORT). The Oncologist, 15: 317-326, 2010.
7) Prof. E. Even-Sapir MD, Prof. M. Inbar
Department of Nuclear Medicine and Division of Oncology, Tel Aviv Sourasky Medical Center, Sackler
School of Medicine, Tel Aviv University, Tel Aviv – Israel.
"PET in women with high risk for breast or ovarian cancer".
The Lancet Oncology, July 7, 2010. DOI:10.1016/S1470-2045.
8) Yavetz D., Corn B., Matsevsky D., Ben Josef R., Soyfer V., Inbar M., Ron I., Schifter D.,: Improved
treatment of the breast and supraclavicular fossa based on a simple geometric principle. Med Dosim,
36: 434-439, 2011.
9) Christina Davies Hongchao Pan, Jon Godwin, Richard Gray, Rodrigo Arriagada, Vinod Raina, Mirta braham,
Victor Hugo Medeiros Alencar, Atef Badran, Xavier Bonfill, Joan Bradbury, Michael Clarke, Rory Collins,
Susan Davis, Antonella Delmestri, John Forbes, Peiman Haddad, Ming-Feng Hou, Moshe Inbar, Hussein
haled Joanna Kielanowska, Wing-Hong Kwan, Beela S Mathew, Bettina Muller, Antonio Nicolucci, Octavio
Peralta, Fany Pernas, Lubos Petruzelka, Tadeusz Pienkowski, Balarishnan Rajan, Maryna T Rubach, Sera
Tort, Gerard Urrutia, Miriam Valentini, Yaochen Wang, Richard Peto, for the Adjuvant Tamoxifen:
Longer Against Shorter (ATLAS) Collaborative Group.
"Effects of adjuvant tamoxifen continued for 10 years versus discontinuation at 5 years for women with
oestrogen receptor-positive breast cancer during the first and the second decade after diagnosis (ATLAS):
a randomized trial".
The Lancet, vol 380, 5 December 2012
10) "Quality of life (QoL) results from the TURANDOT trial comparing two bevacizumab (BEV) – containing
regimens as first line treatment for HER2 – negative metastatic breast cancer (mBC)."
Lang I, Inbar MJ, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Ahlers S, Brodowicz T, Zielinski C,
National Institute of Oncology, Budapest Hungary, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel,
University of Szeged, Hungary, Paracelsus Medical University, Salzburg, Austria; Institute of Oncology,
Sarajevo, Bosnia and Herzegowina; Rabin Medical Center, Petah-Tikva, Israel; Sheba Medical Center,
Ramat Gan Israel, IST GmbH Mannheim, Mannheim Germany, Medical University of Vienna and Central
European Cooperative Oncology Group (CECOG), Vienna Austria.
CTRC-AACR San Antonio Breast Cancer Symposium
Cancer Res, 72(24 Suppl.) December 15, 2012.